Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01242137|
Recruitment Status : Unknown
Verified October 2010 by Assaf-Harofeh Medical Center.
Recruitment status was: Recruiting
First Posted : November 16, 2010
Last Update Posted : November 16, 2010
Glibenclamide is metabolized by the hepatic enzyme P450 CYP2C9 to less active form. Polymorphism of this enzyme demonstrated clinical significance when examined on other drugs from the sulfonylurea drug family, to whom Glibenclamide is included.
The investigators assumption is that patients with less active alleles of the enzyme may show lower dose requirements of the drug for glycemic control, when compared to patients homozygotes to wild-type alleles.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Observational Model:||Case Control|
|Study Start Date :||October 2009|
- HbA1c [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01242137
|Contact: Amit Tirosh, Dremail@example.com|
|Assaf Harofe Medical Center||Recruiting|
|Beer Yakov, Israel|
|Contact: Amit Tirosh, Dr 972-52-4748989 firstname.lastname@example.org|
|Principal Investigator: Amit Tirosh, Dr|